Evidence That D-Dimer Levels Predict Subsequent Thromboembolic and Cardiovascular Events in Patients With Atrial Fibrillation During Oral Anticoagulant Therapy

Objectives
The aim of the present study was to evaluate whether elevated D-dimer levels can predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy.
Background
Atrial fibrillation is associated with hemostatic abnormalities even during oral anticoagulant therapy. D-dimer levels reflect a pro-thrombogenic state and thus might serve as a marker of thromboembolic and cardiovascular events.
Methods
This was a single-center, prospective, observational study. Patients with atrial fibrillation (269 patients, age 74 Ϯ 9 years, 160 paroxysmal atrial fibrillation) treated with warfarin (target prothrombin time-international normalized ratio: 1.5 to 3.0) were included. D-dimer levels were measured to assess the relationship of this parameter with subsequent thromboembolic and cardiovascular events. End points were thromboembolic events and combined cardiovascular events (thromboembolic events, cerebral hemorrhage, myocardial infarction, cardiovascular death).
Results
D-dimer levels were elevated (Ն0.5 g/ml) in 63 (23%) patients. During an average follow-up period of 756 Ϯ 221 days, 10 (1.8%/year) thromboembolic events (8 ischemic strokes, 1 transient ischemic attack, and 1 peripheral embolism) and 27 (4.8%/year) combined cardiovascular events (10 thromboembolisms, 9 deaths from heart failure, 3 sudden deaths, 2 myocardial infarctions, and 3 cerebral hemorrhages) occurred. Patients with elevated D-dimer levels experienced higher thromboembolic and combined cardiovascular events. Cox proportional hazard model revealed that elevated D-dimer levels were associated with both thromboembolic (p Ͻ 0.01, hazard ratio: 15.8; 95% confidence interval: 3.33 to 75.5) and combined cardiovascular (p Ͻ 0.01, hazard ratio: 7.64; 95% confidence interval: 3.42 to 17.1) events. Atrial fibrillation (AF) is associated with hemostatic abnormalities and increased risk of thromboembolic events. Effectiveness of oral anticoagulant therapy in reducing thromboembolic events is well documented (1-3) ; however, levels of coagulation markers are still elevated even during oral anticoagulant therapy in some patients (4 -7). D-dimer originates from the formation and lysis of cross-linked fibrin and reflects activation of coagulation and fibrinolysis; thus, it can be used as an "in vivo" coagulation marker in addition to the standard "in vitro" marker of prothrombin timeinternational normalized ratio (PT-INR). The aim of the present study was to evaluate whether elevated D-dimer levels can predict subsequent thromboembolic and cardiovascular events in patients with AF during oral anticoagulant therapy.
Methods
Patients. This was a single-center, prospective, observational study. Patients eligible for our study were those undergoing AF treatment with warfarin. During entry periods (January 2006 to April 2007), 301 patients were initially screened, and finally 269 patients-152 (57%) male, 109 (41%) chronic AF (AF lasting more than 2 regular office visits), and 160 paroxysmal (or persistent) AF-were enrolled and followed until December 2008 (Fig. 1) . The study protocol was approved by the institutional ethics committee, and informed written consent was obtained from all the patients. Blood sampling and assays. All assays were performed in the laboratory of our institution within 2 h of blood sampling. For the quantitative measurement of D-dimers, a latex-enhanced photometric immunoassay (LPIA, Mitsubishi Chemical Medience Corporation, Tokyo, Japan) was used with automatic analyzer (LPIA-S500). The detection limit of this assay was 0.3 g/ml. Intra-assay and interassay variability (coefficient of variability) was 2.2% and 4.4%, respectively. D-dimer was measured at the time of enrollment and repeated 2 or 3 times during entry period in some patients. The PT-INR was measured every 1 to 2 month throughout the observational periods. Target PT-INR was set at 1.5 to 3.0. End points. The end points were thromboembolic events (ischemic stroke, transient ischemic attack, peripheral embolism) and combined cardiovascular events, which included thromboembolic events, cerebral hemorrhage, myocardial infarction, and cardiovascular deaths. Major bleeding was defined as gastrointestinal bleeding requiring transfusion and intracranial bleeding, including cerebral hemorrhage and subdural hematoma.
Statistical analysis. Data were presented as the mean Ϯ SD or percentages, as appropriate. Event frequencies were compared with the chi-square test. Other comparisons between 2 groups of data were made with unpaired Student t test or Mann-Whitney U test, as appropriate. Correlation analysis was performed by Spearman's rank correlation. The optimal D-dimer cutoff point was evaluated by receiver operator characteristic curve. Logistic regression models were applied to assess the determinants of high D-dimer levels. The outcomes were displayed with Kaplan-Meier event-free curve and compared with the use of log-rank tests. The prognostic values of D-dimer and clinical variables were analyzed with Cox-proportional hazard models. A value of p Ͻ 0.05 was accepted as statistically significant. The statistical software package SPSS (version 11.0, SPSS, Inc., Chicago, Illinois) and StatView (version 5.0 StatView, Berkeley, California) were used for analyses.
Results
Baseline clinical characteristics.
Baseline heart disease included 44 (16%) hypertensive heart disease, 37 (14%) coronary artery disease, 32 (12%) valvular heart disease, 17 (6.3%) hypertrophic cardiomyopathy, and 10 (3.7%) dilated cardiomyopathy. No apparent heart diseases were found in 131 (49%) patients. Other clinical risk factors are shown in Table 1 .
At the time of enrollment, PT-INR levels were 1.93 Ϯ 0.53 (1.2 to 6.9, median 1.82). The PT-INR levels were less optimal (Ͻ1.5) in 32 (12%), exceeded (Ͼ3.0) in 7 (2.6%), and within therapeutic range (1.5 Յ PT-INR Յ3.0) in the remaining 230 (86%) patients ( Death from heart failure (n) 9 6 3 Ͻ0.01
Sudden death (n) 3 0 3 0.34
Bleeding complications (n) 9 8 1 Ͻ0.01
Gastrointestinal bleedings (n) 5 5 0 Ͻ0.01
Thromboembolic events: ischemic stroke, transient ischemic attack, and peripheral embolism. Cardiovascular events: thromboembolism, death from heart failure, sudden death, myocardial infarction, and cerebral hemorrhage. Bleeding complications: gastrointestinal bleeding requiring transfusion and intracranial bleeding. *p value, D-dimer Ն0.5 g/ml versus D-dimer Ͻ0.5 g/ml.
CHF ϭ congestive heart failure (New York Heart Association functional class ՆII). patients. There was a high correlation between the 2 D-dimer measurements (p Ͻ 0.01, ϭ 0.86, by Spearman's rank correlation). The difference between these 2 D-dimer measurements was small (0.21 Ϯ 0.42 g/ml, median 0.01 g/ml). End points and major bleedings. Approximately 80% of the patients were followed in our institution, and the rest were followed by attending physicians who referred the patients to us. During a follow-up time of 756 Ϯ 221 (1 to 1,091; median 740) days, 4 patients discontinued taking warfarin, and 6 were lost to follow-up after 1 year. These 10 patients were included in the final analysis (Fig. 1 ). There were 10 thromboembolic events (1.8%/year): 8 ischemic strokes, 1 transient ischemic attack, and 1 peripheral embolism. There were 27 cardiovascular events (4.8%/year): 10 thromboembolisms, 9 deaths from heart failure, 3 sudden deaths, 2 myocardial infarctions, and 3 cerebral hemorrhages. There were 9 (1.6%/year) major bleedings: 3 cerebral hemorrhages, 1 subdural hematoma, and 5 gastrointestinal bleedings requiring transfusion (Table 1) . Cutoff values and determinants of D-dimer levels. In the current study, the upper quartile of the D-dimer value was 0.48 g/ml. With the receiver operator characteristic curve analysis (Fig. 3) , the optimum cut point, identified as the point closest to upper left corner, yielded optimal cutoff value of approximately 0.5 g/ml to detect both thromboembolic events and cardiovascular events. Previously, most studies used D-dimer cutoff values of 0.5 to 1.0 g/ml for excluding pulmonary embolism (8) and acute aortic dissection (9) . On the basis of these findings, the cutoff value of D-dimer level for the current study was set at 0.5 g/ml.
Median values in patients with high (Ն0.5 g/ml) and low (Ͻ0. 5 g/ml) D-dimer values were 0.86 and 0 g/ml, respectively. The PT-INR levels in patients with high and low D-dimer levels were not different (1.99 Ϯ 0.74, median 1.82, vs. 1.92 Ϯ 0.45, median 1.82, p ϭ 0.83 by MannWhitney U test). Table 1 shows characteristics of patients with high (Ն0.5 g/ml) D-dimer levels. Patients with high D-dimer levels had higher prevalence of congestive heart failure (CHF), older age (Ն75 years), and history of stroke. Table 2 shows determinants of high D-dimer levels by logistic regression analysis. Univariate analysis showed that CHF, age Ն75 years, and history of stroke were the 
Figure 3 Receiver Operator Characteristic Curve for D-Dimer to Predict Thromboembolic and Cardiovascular Events
Area under receiver operator characteristic curve for thromboembolic events (A) and cardiovascular events (B) was 0.82 and 0.74, respectively. Arrows indicate D-dimer cutoff values. The optimum cutoff point, identified as the point closest to upper left corner, was 0.54 g/ml (A) and 0.50 g/ml (B). significant determinants of high D-dimer levels. Multivariate analysis including these 3 parameters, and PT-INR values revealed that these 3 parameters were the independent predictors of high D-dimer levels. High D-dimer levels to predict thromboembolic and cardiovascular events. There were 8 thromboembolic events observed among patients with baseline D-dimer levels Ն0.5 g/ml as compared with 2 such events in those with baseline D-dimer levels Ͻ0.5 g/ml. Kaplan-Meier thromboembolic event-free curves for D-dimer level showed that elevated D-dimer level was the significant predictor of subsequent thromboembolic events (Fig. 4) . Statistical significance of separation between the 2 groups was achieved at 600 days. With regard to PT-INR levels at the time of events, 5 (50%) of the 10 thromboembolic events occurred when the PT-INR levels were Ͻ1.5, and only 1 thromboembolic event took place when the PT-INR level exceeded 2.0. Table 3 shows risk factors for thromboembolic events by Cox proportional hazard analysis. Univariate analysis showed that high D-dimer levels, CHF, and history of stroke were associated with increased thromboembolic events. High D-dimer level was the significant determinant after adjustment of baseline PT-INR (p Ͻ 0.01, hazard ratio: 15.8; 95% confidence interval [CI]: 3.33 to 75.5). Fully-adjusted models were not possible, given the low number of events.
There were 18 combined cardiovascular events observed among patients with baseline D-dimer levels Ն0.5 g/ml, as compared with 9 such events in those with low levels. Kaplan-Meier curves showed that high D-dimer level was the significant predictor of subsequent cardiovascular events (Fig. 5) . Statistical significance of separation between the 2 groups was achieved at 600 days. Table 4 shows risk factors for combined cardiovascular events by Cox proportional hazard analysis. High D-dimer level, CHF, age Ն75 years, diabetes mellitus, and history of stroke were associated with increased cardiovascular events. High D-dimer level was also a significant determinant after adjustment of baseline Determinants of High D-Dimer Levels (>0.5 g/ml) by Logistic Regression Analysis CI ϭ confidence interval; PT-INR ϭ prothrombin time-international normalized ratio.
Figure 4 Kaplan-Meier Thromboembolic Event-Free Curves for D-Dimer Levels During Oral Anticoagulant Therapy
Thromboembolic events are defined as ischemic stroke, transient ischemic attack, and peripheral embolism. D-dimer level was the significant predictor of subsequent thromboembolic events. Statistical significance of separation between the 2 groups was achieved at 600 days. With regard to bleeding complications, 4 (44%) of the 9 events occurred when the PT-INR levels were Ͼ3.0, but 3 (33%) events occurred when the PT-INR levels were Ͻ2.0 (i.e., 1.25, 1.55, 1.86). There were 8 bleeding complications observed among patients with baseline D-dimer levels Ն0.5 g/ml, as compared with 1 such event in those with low levels. Cox proportional analysis revealed that high D-dimer levels were significant correlates of bleeding complications (p Ͻ 0.01, hazard ratio: 29.3; 95% CI: 3.65 to 235) after adjustment of baseline PT-INR. Paroxysmal versus chronic AF. Prevalence of CHF (52% vs. 36%, p Ͻ 0.01) and history of stroke (17% vs. 8%, p ϭ 0.021) were higher in chronic AF than those in paroxysmal AF. However, prevalence of high D-dimer levels (28% vs. 21%, p ϭ 0.19) were comparable between these 2 groups.
Risk Factors for Thromboembolic Events by Cox Proportional Hazard Analysis
Discussion
It is well known that D-dimer levels are increased in patients with AF, and introduction of warfarin decreases D-dimer levels (4). However, D-dimer levels are still elevated even during oral anticoagulant therapy in some patients (4 -7). We have found that they were the high-risk patients who subsequently suffer thromboembolic and cardiovascular events. Clinical significance of D-dimer measurement. Circulating concentration of fibrin D-dimer levels reflect the extent of fibrin turnover. Highly elevated D-dimer values occur in various disorders in which the coagulation system is excessively activated, such as acute venous thromboembolism (8) and acute aortic dissection (9) . It has been suggested that modestly elevated circulating D-dimer values reflect minor increases in blood coagulation, thrombin formation, and turnover of cross-linked intravascular fibrin. These increases might be related to thromboembolic (6) and cardiovascular (7) events. This study was consistent with these results. Interestingly, elevated D-dimer levels also predicted bleeding complications in this study. The reasons were not known, but it can be speculated that the fibrinolytic activation of which D-dimer is a marker might itself predispose to bleeding. Study limitations. First, this is a single-center study, and selection bias is a major concern. We have tried to include every patient with AF who visited our office; however, it is difficult to start anticoagulation therapy in elderly patients with dementia, for fear of overdoses of warfarin, frequent falls, and subsequent bleeding complications. Age Ն75 years was not a risk factor for thromboembolic events partly due to the exclusion of these high-risk patients. Second, target PT-INR in this study was set below the recommended guideline of Western countries (PT-INR: 2.0 to 3.0). The Japanese Secondary Prevention Trial (10) suggested that there might be a racial difference in the optimal anticoagulation intensity for the prevention of ischemic stroke in patients with AF. Japanese guidelines (11) recommended target PT-INR should be 1.6 to 2.6 when the patients were older than 70 years. Anticoagulant therapies should always be considered along with the balance between antithrombotic effect and risk of bleeding. The annual incidence of thromboembolic events (1.8%/year) and bleeding complications (1.6%/year) were similar in this study, suggesting that target PT-INR was probably a reasonable range for the Japanese population. However, it might not be applicable to Western populations. Third, it is speculated that D-dimer levels might be increased at the time of events, but it was measured only at the entry periods, mainly due to budget constraints. Therefore, D-dimer levels at the time of events were unknown. However, reproducibility of D-dimer levels was acceptable in our study as well as in a previous study (5); thus we believe that D-dimer levels at baseline, if anticoagulated in a proper PT-INR range, are an important marker of thromboembolic and cardiovascular events. Finally and most importantly, the number of patients and events in this study was small; therefore further larger-scale, multicenter studies are needed to confirm these findings. Combined cardiovascular events are defined as thromboembolic events, cerebral hemorrhage, myocardial infarction, or cardiovascular death. D-dimer level was the significant predictor of subsequent combined cardiovascular events. Statistical significance of separation between the 2 groups was achieved at 600 days.
Risk Factors for Combined Cardiovascular Events by Cox Proportional Hazard Analysis
